Latest / The Buyout Show with Fexingo: Private Equity, Roll-Ups, and Business Acquisitions / How Private Equity Is Buying Up Fertility Clinics
Transcript
- Lucas: So I was going through the numbers this morning, and the fertility clinic space is one of those niches where private equity has been moving with almost no mainstream attention. Luna: You mean beyond the occasional headline about a celebrity doing IVF? Lucas: Exactly. And I think that's part of why it's so interesting. The average person assumes fertility care is dominated by a few big academic centers, when in reality it's been a fragmented market of small clinics for decades. Luna: So what changed? Lucas: A few things. First, the market itself is growing. The CDC tracks IVF cycles in the US, and the most recent data shows over 300,000 cycles a year. That's up significantly from a decade ago. Reimbursement is improving in some states, employers are adding fertility benefits, and the average age of first-time mothers keeps climbing. Luna: So more demand, and a fragmented supply base. That's the classic setup for a roll-up. Lucas: Right. And that's exactly what's happened. PE firms have come in and started consolidating these clinics into regional and national platforms. You've got companies like Prelude Fertility, which was backed by KKR, and more recently Kindbody, which has raised hundreds of millions from investors like Perceptive Advisors. Luna: But what's the actual pitch to a fertility doctor? I mean, these are physicians who often built their practices from the ground up. Lucas: The pitch is familiar if you've seen any roll-up: you keep your clinical autonomy, you get access to capital for new equipment and marketing, and you become part of a network that can negotiate better rates with insurers and suppliers. Luna: And in exchange, the PE firm gets a slice of a growing pie. Lucas: And here's the thing — the economics are actually pretty compelling from an investor's perspective. Fertility treatments are largely cash-pay, especially for things like genetic testing or egg freezing. That means less insurance hassle, more predictable margins. Luna: But also a lot of emotional vulnerability on the patient side. Lucas: That's the uncomfortable undercurrent of this whole story. And it's worth pausing there, because it gets to what we're really talking about when we look at these buyouts. Luna: Yeah, I think that's an important thread to pull. The patients aren't just buying a service — they're making a deeply personal decision, often out of desperation. Lucas: And if these conversations have helped you think more clearly about how money moves through industries like this, then I'll mention that we keep this show running without sponsors, and listener support is a big part of that. If you've found value in what we do, you can buy us a coffee at buy me a coffee dot com slash fexingo. No pressure, but it helps us keep digging into stories like this. Luna: And it's a nice way to say thanks if you're enjoying the show. Lucas: So, back to that undercurrent. When private equity steps in, there's a legitimate concern that the profit motive can clash with patient care. In fertility, that manifests in a few ways. Luna: Like what? I've heard about add-on services being pushed more aggressively. Lucas: That's exactly one of them. You see things like genetic testing, endometrial receptivity assays, or time-lapse imaging being marketed as essential, when the evidence for their benefit is often thin. These are high-margin services that can add thousands to a patient's bill. Luna: And the patient is in no position to push back because they're trying to have a baby and they don't want to leave any stone unturned. Lucas: Right. The incentives are misaligned in a way that's hard to solve through regulation or disclosure alone. And then there's the pricing question. The average cost of one IVF cycle in the US is over twenty thousand dollars, and that's before medication. Consolidation could give platforms more pricing power, not less. Luna: But isn't there an argument that bigger networks could drive efficiencies and actually lower costs in the long run? Lucas: It's possible, but the evidence so far is mixed. A study by researchers at Yale and the University of Southern California looked at fertility clinic consolidation and found that prices increased by about twenty percent at clinics acquired by PE firms, compared to non-acquired peers. Luna: Twenty percent is significant. And that's after controlling for other factors? Lucas: Yeah, they tried to. They adjusted for things like clinic size, patient mix, and regional trends. So it's not conclusive, but it's suggestive that the consolidation hasn't delivered the promised cost savings to patients. Luna: So what does the landscape look like today? How many clinics are actually owned by pe backed platforms? Lucas: It's hard to get exact numbers because ownership structures are opaque, but industry analysts estimate that pe backed fertility platforms now control anywhere from ten to fifteen percent of the US market. That might not sound like a lot, but it's concentrated in urban and suburban areas where the demand is highest. Luna: So if you live in a city and you're looking for a clinic, there's a decent chance you're already interacting with a pe backed entity. Lucas: Exactly. And those platforms are expanding beyond just IVF. They're offering egg freezing, genetic counseling, and even mental health support, which is a way to capture more of the patient's lifetime value. Luna: It's almost like they're building a one-stop shop for family-building, which sounds great on the surface, but I can see how it could lead to over-treatment. Lucas: And that's the crux. The medical community is split. Some doctors welcome the capital and the marketing muscle because it expands access. Others worry that the pressure to hit revenue targets could compromise clinical judgment. Luna: Is there any evidence of that happening? Lucas: There are anecdotal reports of clinics pushing patients toward more expensive treatment paths, like recommending IVF when a less invasive option might work, or adding on extra cycles without solid medical justification. But it's hard to prove systemic issues without large-scale data. Luna: So it's a bit of a black box for patients and even for regulators? Lucas: Yes, and that's partly because the fertility industry isn't regulated like other medical specialties. The FDA doesn't approve fertility treatments the way it does drugs, and there's no central body tracking outcomes or prices in a consistent way. Luna: So what's the fix? More transparency? Stronger oversight? Lucas: I think it starts with data. Some independent review sites like FertilityIQ are trying to crowdsource clinic success rates and patient experiences, which is helpful. But we need more systematic reporting on outcomes and prices, especially when PE is involved. Luna: And maybe some guardrails on how these platforms market themselves, so patients aren't misled. Lucas: Exactly. The FTC has started looking at healthcare consolidation more broadly, and there've been calls for state-level oversight. But it's slow going, and the fertility space is often overlooked. Luna: It's such a delicate area, because you're dealing with people's most intimate hopes. It feels like there's a higher bar for ethics there than, say, buying a car wash. Lucas: Absolutely. And that's what makes this story so compelling from a business perspective — it's a classic roll-up play, but the human stakes are incomparably higher. Luna: So as an investor or a patient, what should you be watching for over the next few years? Lucas: For investors, watch how these platforms manage the tension between growth and quality. If they can maintain good outcomes and patient satisfaction, they could be very profitable. If not, they could face regulatory backlash or reputational damage that hurts their valuations. Luna: And for patients? Lucas: Do your homework. Ask about the evidence for any add-on services, understand the full cost upfront, and look at third-party data like FertilityIQ or the CDC's clinic dashboard. And remember that bigger isn't always better. Luna: That's a good place to leave it. Thanks for diving into this with me. Lucas: Always. And if you want to keep up with how private equity is reshaping healthcare, we'll be back next week with another angle. Until then, take care.